Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Alkermes (ALKS – Research Report) today and set a price target of ...

In the assessment of 12-month price targets, analysts unveil insights for Alkermes, presenting an average target of $37.14, a high estimate of $50.00, and a low estimate of $25.00. This current ...

Alkermes plc ALKS reported adjusted earnings from continuing operations of 44 cents per share for first-quarter 2024, which ...

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Hold rating on Alkermes (ALKS – Research Report), with a price ...

Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the ...

ALKS stock results show that Alkermes missed analyst estimates for earnings per share and missed on revenue for the first ...

An RCT suggests transcranial alternating current stimulation may be an effective treatment for major depression, but outside ...

DUBLIN — DUBLIN — Alkermes PLC (ALKS) on Wednesday reported first-quarter net income of $36.8 million, after reporting a loss in the same period a year earlier. The Dublin-based company said it had ...

Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the ...

Q1 earnings growth expectations have sharply declined more than usual as we enter earnings season. Over the past three months, Q1 growth projections have been adjusted downward by 21.5 percentage ...

The Wilmington-Clinton County Chamber of Commerce’s 2024 Annual Meeting, a hallmark event for local businesses and community ...

Alkermes (ALKS) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.01 per share a year ago. These figures are ...